SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on June 7, 2002; DOI 10.1182/blood-2002-03-0989. This Article Full Text (PDF) All Versions of this Article: 2002-03-0989v1 100/6/1984    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Spina, M. Articles by Tirelli, U. Search for Related Content PubMed PubMed Citation Articles by Spina, M. Articles by Tirelli, U. Social Bookmarking                   What's this? Submitted April 1, 2002 Accepted April 30, 2002 Stanford V regimen and concomitant HAART in 59 patients with Hodgkin's disease and HIV infection Michele Spina*, Jean Gabarre, Giuseppe Rossi, Marco Fasan, Clara Schiantarelli, Ezio Nigra, Maurizio Mena, Andrea Antinori, Adriana Ammassari, Renato Talamini, Emanuela Vaccher, Giampiero di Gennaro, and Umberto Tirelli Division of Medical Oncology A, National Cancer Institute, Aviano, PN, Italy Department of Hematology, Hospital Pitie-Salpetriere, Paris, France Hematology Unit, Spedali Civili, Brescia, Italy Department of Infectious Diseases, Sacco Hospital, Milan, Italy Division of Infectious Diseases, Niguarda Hospital, Milan, Italy Division of Infectious Diseases B, Amedeo di Savoia Hospital, Turin, Italy Division of Infectious Diseases, Cuggiono Hospital, Cuggiono, Italy Department of Clinical Research, IRCCS L Spallanzani, Rome, Italy Department of Infectious Diseases, Universita Cattolica del S Cuore, Rome, Italy Epidemiology Unit, National Cancer Institute, Aviano, PN, Italy * Corresponding author; email: oma{at}cro.it. A phase II prospective study was performed in order to evaluate how feasible and active a short, dose-intensity chemotherapy regimen and radiotherapy (Stanford V) plus highly active antiretroviral therapy (HAART) and granulocyte colony-stimulating factor (G-CSF) support is in patients with Hodgkin's disease and HIV infection. Fifty-nine patients were enrolled. Stanford V was well tolerated and 69% of the patients completed treatment with no dose reduction or delayed chemotherapy administration. The most important dose-limiting side effects were bone marrow toxicity and neurotoxicity. Eighty-one percent of the patients achieved complete remission and after a median follow-up of 17 months 33/59 (56%) patients are alive and disease-free. The estimated 3-year overall survival (OS), disease-free survival (DFS) and freedom from progression (FFP) were 51%, 68% and 60%, respectively. Probability FFP was significantly (p=0.02) higher among patients with an international prognostic score (IPS) of 2 than in those with IPS > 2, and the percentage of FFP at two years were 83% and 41% respectively. Similarly, probability OS was significant different (p = 0.0004), and the percentage of survival at three years were 76% and 33% respectively for IPS 2 and IPS>2. Our data confirm Stanford V regimen with concomitant HAART is feasible and active in an HIV setting. However, a more intensive approach should be considered in patients with high IPS. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. Re, M. Michieli, S. Casari, B. Allione, C. Cattaneo, M. Rupolo, M. Spina, R. Manuele, E. Vaccher, M. Mazzucato, et al. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors Blood, August 13, 2009; 114(7): 1306 - 1313. [Abstract] [Full Text] [PDF] J.-P. Spano, D. Costagliola, C. Katlama, N. Mounier, E. Oksenhendler, and D. Khayat AIDS-Related Malignancies: State of the Art and Therapeutic Challenges J. Clin. Oncol., October 10, 2008; 26(29): 4834 - 4842. [Abstract] [Full Text] [PDF] J. M. Connors Challenging Problems: Coincident Pregnancy, HIV Infection, and Older Age Hematology, January 1, 2008; 2008(1): 334 - 339. [Abstract] [Full Text] [PDF] A. Garcia-Noblejas, S. Nieto, R. Liberal, J. Cannata, J.L. Steegmann, J.M. Fernandez-Ranada, and R. Arranz Intracerebral hogkin's lymphoma in a patient with human immunodeficiency virus Haematologica, June 1, 2007; 92(6): e72 - e73. [Abstract] [Full Text] [PDF] B. Xicoy, J.-M. Ribera, P. Miralles, J. Berenguer, R. Rubio, B. Mahillo, M.-E. Valencia, E. Abella, A. Lopez-Guillermo, A. Sureda, et al. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma Haematologica, February 1, 2007; 92(2): 191 - 198. [Abstract] [Full Text] [PDF] M. Hentrich, L. Maretta, K. U. Chow, J. R. Bogner, D. Schurmann, P. Neuhoff, H. Jager, D. Reichelt, M. Vogel, M. Ruhnke, et al. Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study Ann. Onc., June 1, 2006; 17(6): 914 - 919. [Abstract] [Full Text] [PDF] W. H. Navarro and L. D. Kaplan AIDS-related lymphoproliferative disease Blood, January 1, 2006; 107(1): 13 - 20. [Abstract] [Full Text] [PDF] S. T. Lim and A. M. Levine Recent Advances in Acquired Immunodeficiency Syndrome (AIDS)-related Lymphoma CA Cancer J Clin, July 1, 2005; 55(4): 229 - 241. [Abstract] [Full Text] [PDF] M. C. Cheung, L. Pantanowitz, and B. J. Dezube AIDS-Related Malignancies: Emerging Challenges in the Era of Highly Active Antiretroviral Therapy Oncologist, June 1, 2005; 10(6): 412 - 426. [Abstract] [Full Text] [PDF] A. Krishnan, A. Molina, J. Zaia, D. Smith, D. Vasquez, N. Kogut, P. M. Falk, J. Rosenthal, J. Alvarnas, and S. J. Forman Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas Blood, January 15, 2005; 105(2): 874 - 878. [Abstract] [Full Text] [PDF] A. Re, C. Cattaneo, M. Michieli, S. Casari, M. Spina, M. Rupolo, B. Allione, A. Nosari, C. Schiantarelli, M. Vigano, et al. High-Dose Therapy and Autologous Peripheral-Blood Stem-Cell Transplantation As Salvage Treatment for HIV-Associated Lymphoma in Patients Receiving Highly Active Antiretroviral Therapy J. Clin. Oncol., December 1, 2003; 21(23): 4423 - 4427. [Abstract] [Full Text] [PDF] P. Hartmann, U. Rehwald, B. Salzberger, C. Franzen, M. Sieber, A. Wohrmann, and V. Diehl BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection Ann. Onc., October 1, 2003; 14(10): 1562 - 1569. [Abstract] [Full Text] [PDF] P. A. Volberding, K. R. Baker, and A. M. Levine Human Immunodeficiency Virus Hematology Hematology, January 1, 2003; 2003(1): 294 - 313. [Abstract] [Full Text] [PDF]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020